For Healthcare Professionals Only.
YUFLYMA® is a tumor necrosis factor (TNF) blocker indicated for:
- Rheumatoid Arthritis (RA) : reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
- Juvenile Idiopathic Arthritis (JIA) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
- Psoriatic Arthritis (PsA) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.
- Ankylosing Spondylitis (AS) : reducing signs and symptoms in adult patients with active AS.
- Crohn’s Disease (CD) : treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- Ulcerative Colitis (UC) : treatment of moderately to severely active ulcerative colitis in adults.
Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. - Plaque Psoriasis (Ps) : treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- Hidradenitis Suppurativa (HS) : treatment of adult patients with moderate to severe hidradenitis suppurativa.
Login to read more
